What Medpace Holdings, Inc. does.

We are one of the world’s leading clinical contract research organizations, or CROs, by revenue, solely focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Our mission is to accelerate the global development of safe and effective medical therapeutics. We differentiate ourselves from our competitors by our disciplined operating model centered on providing full-service Phase I-IV clinical development services and our therapeutic expertise. We believe this combination results in timely and cost-effective delivery of clinical development services for our customers. We believe that we are a partner of choice for small and mid-sized biopharmaceutical companies based on our ability to consistently utilize our full-service, disciplined operating model to deliver timely and high-quality results for our customers. Accordingly, our business strategy aims to continue to expand our market share in the growing Phase I-IV CRO market as we conduct clinical trials across all major therapeutic areas, with particular strength in Oncology, Metabolic, Cardiology, Antiviral and Anti-infective (AVAI) and Central Nervous System (CNS).

Revenue and profit, by fiscal year.

More on MEDP.

• Medpace Holdings, Inc. summary
• Medpace Holdings, Inc. financial statements
• Medpace Holdings, Inc. key metrics
• Medpace Holdings, Inc. health scores and style box
• Medpace Holdings, Inc. earnings
• Medpace Holdings, Inc. dividends
• Medpace Holdings, Inc. valuation
• Medpace Holdings, Inc. ownership and insiders
• Medpace Holdings, Inc. peers

Figures from Medpace Holdings, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.